Results 41 to 50 of about 48,636 (310)
An oncolytic measles virus engineered to enter cells through the CD20 antigen
Molecular Therapy, 2003 We have earlier shown that attenuated measles virus (MV) has therapeutic potential as a replicating oncolytic virus in models of non-Hodgkin's lymphoma (NHL). In the current study, we investigated whether we could obtain replicating MVs capable of entering CD20(+) target cells through an interaction between a single-chain (scFv) anti-CD20 antibody and ...
Bucheit, Amanda D +6 more
openaire +2 more sources
Construction and evaluation of wild and mutant ofatumumab scFvs against the human CD20 antigen
Preparative Biochemistry & Biotechnology, 2022 Several monoclonal antibodies targeting the CD20 have been produced and Ofatumumab is a case in point. Although whole antibodies target cancer cells effectively, their applications are restricted in some ways. Single-chain fragment variable antibodies, rather than employing the entire structure of antibodies, have proven a practical approach for ...
Reza Maleki +2 more
openaire +2 more sources
Identification and validation of targets for cancer immunotherapy: from the bench-to-bedside [PDF]
, 2013 Chapter 12 in Novel Gene Therapy ...
Brooks, Suzanne E. +4 more
core +3 more sources
Human natural killer cell committed thymocytes and their relation to the T cell lineage. [PDF]
, 1993 Recent studies have demonstrated that mature natural killer (NK) cells can be grown from human triple negative (TN; CD3-, CD4-, CD8-) thymocytes, suggesting that a common NK/T cell precursor exists within the thymus that can give rise to both NK cells ...
Lanier, LL +3 more
core +1 more source
Use of single-chain antibody derivatives for targeted drug delivery [PDF]
, 2016 Single-chain antibodies (scFvs), which contain only the variable domains of full-length antibodies, are relatively small molecules that can be used for selective drug delivery.
Ahmadzadeh, V. +5 more
core +1 more source
Journal for ImmunoTherapy of CancerBackground A bidirectional promoter-driven chimeric antigen receptor (CAR) cassette provides the simultaneous expression of two CARs, which significantly enhances dual antigen-targeted CAR T-cell therapy.Methods We developed a second-generation CAR ...
Supannikar Tawinwung +6 more
doaj +1 more source
Alʹmanah Kliničeskoj Mediciny, 2016 Background: Despite the number of publications related to the expression of surface antigens of periphery blood lymphocytes in chronic obstructive pulmonary disease (COPD), algorithm for interpreting of the results and implicating pathogene-tic ...
N. A. Raspopina +4 more
doaj +1 more source
Disease progression after R-CHOP treatment associated with the loss of CD20 antigen expression [PDF]
Revista Brasileira de Hematologia e Hemoterapia, 2010 A case of a follicular lymphoma transformed into a CD20(+) is described which progressed with the loss of CD20 expression after 8 cycles of R-CHOP. This phenomenon is not a rare event and has shown poor prognosis. Our purposes are to describe this event and suggest biopsy in relapsed or progressive disease.
Bellesso, Marcelo +5 more
openaire +5 more sources
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Background Myasthenia gravis (MG) is an autoimmune disorder characterized by antibody‐mediated complement activation. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, is approved for treating generalized MG (gMG). However, its modulatory effects on upstream innate and adaptive immune cells remain largely unexplored.
Lei Jin +11 more
wiley +1 more source
Anti-CD20 Immunoglobulin G Radiolabeling with a 99mTc-Tricarbonyl Core: In Vitro and In Vivo Evaluations. [PDF]
PLoS ONE, 2015 In recent years, the diagnostic and therapeutic uses of radioisotopes have shown significant progress. Immunoglobulin (Ig) appears to be a promising tracer, particularly due to its ability to target selected antigens.
Hélène Carpenet +3 more
doaj +1 more source